Are Bitovil/Bikernoprenol tablets blocking drugs?

Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate is an oral combination drug used to treat human immunodeficiency virus (HIV) infection, usually used in adult and pediatric patients. It is a combination of three ingredients, including Bictegravir, Emtricitabine and Tenofovir Alafenamide. These three components respectively play different roles and jointly inhibit the replication and spread of HIV.

Bikran is an integrase inhibitor that effectively prevents the integration and replication of the virus by preventing the genetic material of the HIV virus from combining with the DNA of the host cell. Emtricitabine and afanate are nucleotide reverse transcriptase inhibitors (NRTIs). They prevent HIV from transcribing its RNA into DNA by interfering with the reverse transcription process, and therefore can also effectively inhibit the proliferation of the virus. This combination therapy can significantly reduce the viral load in the body and help patients achieve and maintain an "undetectable" status, thereby effectively reducing the risk of HIV transmission.

The advantage of Bituvi is its simplified medication regimen, which usually only requires oral administration once a day and does not need to be taken with food, which greatly facilitates patient medication compliance. In addition, the drug was well tolerated in clinical trials, with relatively mild side effects, and most patients adapted well to this treatment regimen.

Although Bitovil is not a "blocking drug" in the traditional sense, it also shows certain potential in preventing HIV transmission. For high-risk groups, the use of Bituvail can effectively reduce the risk of infection. This characteristic makes the drug attract attention in the field of HIV prevention, especially in the prevention of mother-to-child transmission and high-risk behavior groups.

Reference materials:https://www.biktarvy.com/